PCI Biotech to present at Immunotherapy Forum 2015
Lysaker, January 27, 2015 - PCI Biotech announced that the company will be presenting at the Immunotherapy Forum 2015. The forum is hosted by Phacilitate and takes place January 26-28 in Washington, DC, USA.
The presentation will be held January 27 local time 11:00 at Grand Hyatt Washington and the company will be represented by Dr. Anders Høgset, CSO. The presentation is available below.
PCI Biotech Immunotherapy Forum Jan 2015
About Immunotherapy Forum
The 5th Annual Immunotherapy Forum is focused exclusively on active immunotherapeutic technologies, covering both clinical development and bioprocessing strategy, alongside business model insights provided by leading pharma and biotech players, the FDA, academic thought leaders and other key external stakeholders.
About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange (Axess). The company is developing therapeutic products based on its proprietary photochemical internalization (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI technology works by inducing triggered endosomal release and may be used to unlock the true therapeutic potential of a wide array of modalities, such as small molecules, ADCs and siRNA. Two programs are currently in clinical development in patient populations with a high unmet medical need; recurrent head & neck cancer (phase II) and bile duct cancer (phase I/II).
The company is also developing PCI as a CTL induction technology for therapeutic and prophylactic vaccination. It has been demonstrated both in vivo and ex vivo that PCI significantly increases the number of activated antigen-specific CTLs (Cytotoxic T Lymphocytes) by enhancing the MHC I antigen presentation of antigen presenting cells. When applied more specifically to the emerging field of cancer immunotherapy, PCI can be used to enhance the important cytotoxic effect of therapeutic cancer vaccines. PCI Biotech follows a strategy to create value by improving the effect both of existing cancer drugs and by realizing the large potential in new therapeutics, including therapeutic vaccines.